Allogeneic hematopoietic cell transplantation can cure hematologic malignancies, but its full potential islimited primarily by graft-versus-host disease. Beneficial allo-immune responses target minorhistocompatibility antigens (mHA) expressed on hematopoietic tumor cells resulting in beneficial graft-versus-leukemia responses. However, when donor lymphocytes target mHA expressed by normal recipienttissues, patients suffer both acute and chronic GVHD. Our research shows 50% of male transplant patientswith female donors develop antibodies against mHA encoded on the Y-chromosome, called H-Y antigens.The development of antibodies against any H-Y correlates with cGVHD development (p<0.0001). Thissuggests allogeneic B cell responses may contribute to cGVHD pathogenesis, and supports a trial of anti-Bcell therapy for cGVHD. Dr. Miklos has completed a phase l/ll trial of rituximab therapy for steroid refractorycGVHD patients. Twenty-one patients were treated with one or two courses of Rituximab (375mg/m2 x 4weeks), and their overall response rate was 70% with one year of follow-up. Thus, our research has yieldedtwo insights into the pathogenesis of cGVHD. Allogeneic antibody development correlates with thedevelopment of cGVHD, and anti-B cell therapy is a promising therapy for patients with cGVHD.Hypothesis: Allogeneic antibody responses contribute to chronic GHVD pathogenesis, and serumcollected from cGVHD patients canidentify clinically relevant minor histocompatibility antigens.Our laboratory has developed assays to quantify allogeneic and protective anti-viral antibody responses inrelation to clinical outcomes. Our two rituximab trials in the PPG (in this Project and in Project 1) provideunique opportunities to measure these antibody effects in relation to clinical outcomes when depleting donorB cells after allogeneic transplantation. Serologic screening of a 5000 human protein microarray will identifycandidate mHA as being recognized by patient sera after HCT but not before. Novel mHA will be confirmedby SNP genotyping of donor/recipient pairs for mHA disparity in relation to allogeneic antibody detection.
Specific Aims : 1 Determine if rituximab added to prednisone therapy for newly diagnosed cGVHD patients provides a steroid-sparing benefit with improved cGVHD control. 2a Using microarray technology, determine the temporal development of H-Y antibody in relation to clinical outcomes, especially cGVHD and disease relapse. 2b Determine if in vivo B cell depletion using rituximab prevents/decreases allogeneic antibody development in relation to cGVHD. 3 Serological Identification of human GVHD minor histocompatibility antigens.
Showing the most recent 10 out of 307 publications
